Community-Acquired Pneumonia Treatment Guidelines for Patients with Beta-Lactam and Fluoroquinolone Allergies

Primary Recommendation: Doxycycline Monotherapy

The American Thoracic Society and Infectious Diseases Society of America recommend doxycycline 100 mg orally twice daily as an appropriate monotherapy option for outpatient community-acquired pneumonia, with an initial loading dose of 200 mg to achieve adequate serum levels more rapidly 1, 2
Treatment duration is typically 5-7 days for uncomplicated cases, as recommended by the Infectious Diseases Society of America 1, 3
Doxycycline provides broad-spectrum coverage against common CAP pathogens, including Streptococcus pneumoniae, Haemophilus influenzae, and atypical organisms, according to the American Thoracic Society 1, 4

Azithromycin 500 mg orally on day 1, then 250 mg daily for 4 more days, is an alternative option, but only if local pneumococcal macrolide resistance is documented to be less than 25%, as recommended by the Infectious Diseases Society of America 3, 4
Clarithromycin 500 mg orally twice daily for 5-7 days is another alternative, with the same caveat regarding local resistance, according to the American Thoracic Society 3, 4

Patients with comorbidities, such as chronic heart, lung, liver, or renal disease, typically require combination therapy or respiratory fluoroquinolone monotherapy, but fluoroquinolones are contraindicated in this case, as noted by the American College of Physicians 2, 5
Doxycycline monotherapy remains appropriate even for patients with comorbidities when beta-lactams and fluoroquinolones cannot be used, according to the Infectious Diseases Society of America 1

Photosensitivity is a potential side effect of doxycycline that patients should be counseled about, as recommended by the American Academy of Dermatology 1
If the patient has received doxycycline within the past 3 months, an alternative antibiotic class should be selected due to resistance concerns, according to the Centers for Disease Control and Prevention 1
Doxycycline should not be used if there are risk factors for Pseudomonas aeruginosa infection, such as recent hospitalization or frequent antibiotic use, as noted by the Infectious Diseases Society of America 4

If the patient has a CRB-65 score ≥2, hospitalization should be considered, as recommended by the American College of Emergency Physicians 3
Signs of severe pneumonia requiring ICU admission include respiratory failure, septic shock, or multilobar involvement, according to the Society of Critical Care Medicine 2, 5

The recommendation for doxycycline is based on conditional recommendation with low quality evidence for monotherapy in healthy outpatients, as noted by the American Thoracic Society and Infectious Diseases Society of America 1, 2
However, doxycycline's broad spectrum against both typical and atypical CAP pathogens makes it the most rational choice when both beta-lactams and fluoroquinolones are contraindicated, according to the Infectious Diseases Society of America 1